Valneva Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Valneva hat ein Gesamteigenkapital von €189.2M und eine Gesamtverschuldung von €181.4M, was einen Verschuldungsgrad von 95.9% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen €502.8M bzw. €313.6M.

Wichtige Informationen

95.9%

Verhältnis von Schulden zu Eigenkapital

€181.45m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	€176.64m
Eigenkapital	€189.23m
Gesamtverbindlichkeiten	€313.60m
Gesamtvermögen	€502.83m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: AYJDie kurzfristigen Aktiva des Unternehmens (€306.2M) übersteigen seine kurzfristigen Passiva (€116.1M).

Langfristige Verbindlichkeiten: AYJDie kurzfristigen Vermögenswerte des Unternehmens (€306.2M) übersteigen seine langfristigen Verbindlichkeiten (€197.5M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: AYJDie Nettoverschuldung im Verhältnis zum Eigenkapital (2.5%) wird als zufriedenstellend angesehen.

Schulden abbauen: AYJDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 11.7% auf 95.9% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: AYJ hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: Unzureichende Daten, um festzustellen, ob AYJ über genügend Cash Runway verfügt, wenn sein freier Cashflow auf der Grundlage historischer Raten weiter wächst oder schrumpft.

Valneva Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

First quarter 2024 earnings released: EPS: €0.42 (vs €0.13 loss in 1Q 2023)

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Full year 2023 earnings released: €0.73 loss per share (vs €1.24 loss in FY 2022)

New minor risk - Profitability

Now 20% undervalued after recent price drop

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Forecast to breakeven in 2024

Valneva Se Announces Earnings Guidance for 2024

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

No longer forecast to breakeven

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Third quarter 2023 earnings released: €0.25 loss per share (vs €0.68 profit in 3Q 2022)

New minor risk - Share price stability

Valneva Se Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: €0.12 loss per share (vs €1.34 loss in 2Q 2022)

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

New minor risk - Financial position

Valneva SE announced a financing transaction

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Forecast breakeven date moved forward to 2023

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE Provides Financial Guidance of 2023

First quarter 2023 earnings released: €0.13 loss per share (vs €0.24 loss in 1Q 2022)

No longer forecast to breakeven

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001

Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Investor sentiment improved over the past week

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Valneva SE Reiterates Earnings Guidance for the Fiscal 2022

Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientific Conferences

Valneva SE announced a financing transaction

No longer forecast to breakeven

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

Valneva SE Confirms World Health Organization Recommendations for its Inactivated COVID-19 Vaccine

Valneva SE Initiates Rolling Submission of U.S. Food and Drug Administration Biologics License Application for Its Single Shot Chikungunya Vaccine Candidate

Second quarter 2022 earnings released: €1.34 loss per share (vs €0.60 loss in 2Q 2021)

Valneva SE Provides Revenue Guidance for the Fiscal Year 2022

Pfizer Inc. and Valneva SE Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Forecast breakeven date pushed back to 2024

Valneva Announces Initiation of the Phase 3 Study of Lyme Disease Vaccine

Valneva SE Announces Supervisory Board Member Appointments

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen